{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:08:25Z","timestamp":1785168505188,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89325-1","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T13:02:36Z","timestamp":1739624556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of hepatocellular carcinoma incidence after long-term treatment with besifovir vs. tenofovir AF"],"prefix":"10.1038","volume":"15","author":[{"given":"Hyuk","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon E.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Jin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ju","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Gyune","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"89325_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.17998\/jlc.2024.03.13","volume":"24","author":"DY Kim","year":"2024","unstructured":"Kim, D. Y. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. J. Liver Cancer. 24, 62\u201370. https:\/\/doi.org\/10.17998\/jlc.2024.03.13 (2024).","journal-title":"J. Liver Cancer"},{"key":"89325_CR2","doi-asserted-by":"publisher","unstructured":"Korean Liver Cancer, A., National, C. & Center, K. KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. J. Liver Cancer 23, 1\u2013120. https:\/\/doi.org\/10.17998\/jlc.2022.11.07 (2023).","DOI":"10.17998\/jlc.2022.11.07"},{"key":"89325_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3350\/cmh.2022.0084","volume":"28","author":"Korean Association for the Study of the L","year":"2022","unstructured":"Korean Association for the Study of. The, L. KASL clinical practice guidelines for management of chronic hepatitis B. Clin. Mol. Hepatol. 28, 276\u2013331. https:\/\/doi.org\/10.3350\/cmh.2022.0084 (2022).","journal-title":"Clin. Mol. Hepatol."},{"key":"89325_CR4","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3350\/cmh.2022.0420","volume":"29","author":"YC Hsu","year":"2023","unstructured":"Hsu, Y. C., Tseng, C. H. & Kao, J. H. Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: first, do no harm. Clin. Mol. Hepatol. 29, 869\u2013890. https:\/\/doi.org\/10.3350\/cmh.2022.0420 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"89325_CR5","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/gutjnl-2013-305138","volume":"63","author":"CL Lai","year":"2014","unstructured":"Lai, C. L. et al. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut 63, 996\u20131004. https:\/\/doi.org\/10.1136\/gutjnl-2013-305138 (2014).","journal-title":"Gut"},{"key":"89325_CR6","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.cgh.2018.11.001","volume":"17","author":"SH Ahn","year":"2019","unstructured":"Ahn, S. H. et al. Efficacy and safety of besifovir dipivoxil maleate compared with tenofovir disoproxil fumarate in treatment of chronic hepatitis B virus infection. Clin. Gastroenterol. Hepatol. 17, 1850\u20131859. https:\/\/doi.org\/10.1016\/j.cgh.2018.11.001 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"89325_CR7","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3390\/biomedicines10071637","volume":"10","author":"J Won","year":"2022","unstructured":"Won, J. et al. Susceptibility of drug resistant hepatitis B virus mutants to besifovir. Biomedicines 10, 1637. https:\/\/doi.org\/10.3390\/biomedicines10071637 (2022).","journal-title":"Biomedicines"},{"key":"89325_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.5009\/gnl220390","volume":"18","author":"TH Kim","year":"2024","unstructured":"Kim, T. H. et al. Noninferiority outcomes of besifovir compared to tenofovir alafenamide in treatment-na\u00efve patients with chronic hepatitis B. Gut Liver. 18, 305\u2013315. https:\/\/doi.org\/10.5009\/gnl220390 (2024).","journal-title":"Gut Liver"},{"key":"89325_CR9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.14309\/ajg.0000000000000605","volume":"115","author":"HJ Yim","year":"2020","unstructured":"Yim, H. J. et al. Besifovir dipivoxil maleate 144-week treatment of chronic hepatitis B: an open-label extensional study of a phase 3 trial. Am. J. Gastroenterol. 115, 1217\u20131225. https:\/\/doi.org\/10.14309\/ajg.0000000000000605 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"89325_CR10","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1111\/liv.15388","volume":"42","author":"CY Jung","year":"2022","unstructured":"Jung, C. Y. et al. Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B. Liver Int. 42, 2408\u20132417. https:\/\/doi.org\/10.1111\/liv.15388 (2022).","journal-title":"Liver Int."},{"key":"89325_CR11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jhep.2014.10.026","volume":"62","author":"MF Yuen","year":"2015","unstructured":"Yuen, M. F. et al. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. J. Hepatol. 62, 526\u2013532. https:\/\/doi.org\/10.1016\/j.jhep.2014.10.026 (2015).","journal-title":"J. Hepatol."},{"key":"89325_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3350\/cmh.2020.0307","volume":"27","author":"DS Song","year":"2021","unstructured":"Song, D. S. et al. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: results of 192-week phase 3 trial. Clin. Mol. Hepatol. 27, 346\u2013359. https:\/\/doi.org\/10.3350\/cmh.2020.0307 (2021).","journal-title":"Clin. Mol. Hepatol."},{"key":"89325_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","volume":"5","author":"J Choi","year":"2019","unstructured":"Choi, J. et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean Nationwide Cohort Study. JAMA Oncol. 5, 30\u201336. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4070 (2019).","journal-title":"JAMA Oncol."},{"key":"89325_CR14","doi-asserted-by":"publisher","first-page":"e0224773","DOI":"10.1371\/journal.pone.0224773","volume":"14","author":"MB Chen","year":"2019","unstructured":"Chen, M. B. et al. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: a systematic review and meta-analysis. PLoS ONE. 14, e0224773. https:\/\/doi.org\/10.1371\/journal.pone.0224773 (2019).","journal-title":"PLoS ONE"},{"key":"89325_CR15","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3390\/nu12071915","volume":"12","author":"T Hanai","year":"2020","unstructured":"Hanai, T. et al. Usefulness of carnitine supplementation for the complications of liver cirrhosis. Nutrients 12, 915. https:\/\/doi.org\/10.3390\/nu12071915 (2020).","journal-title":"Nutrients"},{"key":"89325_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.23623","volume":"52","author":"G Musso","year":"2010","unstructured":"Musso, G., Gambino, R., Cassader, M. & Pagano, G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52, 79\u2013104. https:\/\/doi.org\/10.1002\/hep.23623 (2010).","journal-title":"Hepatology"},{"key":"89325_CR17","doi-asserted-by":"publisher","first-page":"689042","DOI":"10.3389\/fmed.2021.689042","volume":"8","author":"N Li","year":"2021","unstructured":"Li, N. & Zhao, H. Role of Carnitine in non-alcoholic fatty liver disease and other related diseases: an update. Front. Med. (Lausanne). 8, 689042. https:\/\/doi.org\/10.3389\/fmed.2021.689042 (2021).","journal-title":"Front. Med. (Lausanne)"},{"key":"89325_CR18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/jgh.16178","volume":"38","author":"K Murata","year":"2023","unstructured":"Murata, K. & Mizokami, M. Possible biological mechanisms of entecavir versus tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 38, 683\u2013691. https:\/\/doi.org\/10.1111\/jgh.16178 (2023).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"89325_CR19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/jgh.15710","volume":"37","author":"HJ Yim","year":"2022","unstructured":"Yim, H. J. et al. Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients. J. Gastroenterol. Hepatol. 37, 378\u2013386. https:\/\/doi.org\/10.1111\/jgh.15710 (2022).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"89325_CR20","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3390\/cancers16050887","volume":"16","author":"HJ Yim","year":"2024","unstructured":"Yim, H. J. et al. Reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B receiving long-term besifovir therapy. Cancers (Basel). 16, 887. https:\/\/doi.org\/10.3390\/cancers16050887 (2024).","journal-title":"Cancers (Basel)"},{"key":"89325_CR21","doi-asserted-by":"publisher","first-page":"100847","DOI":"10.1016\/j.jhepr.2023.100847","volume":"5","author":"YS Lim","year":"2023","unstructured":"Lim, Y. S. et al. Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B. JHEP Rep. 5, 100847. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100847 (2023).","journal-title":"JHEP Rep."},{"key":"89325_CR22","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1111\/jvh.13601","volume":"28","author":"HW Lee","year":"2021","unstructured":"Lee, H. W. et al. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. J. Viral Hepat. 28, 1570\u20131578. https:\/\/doi.org\/10.1111\/jvh.13601 (2021).","journal-title":"J. Viral Hepat."},{"key":"89325_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jclinepi.2022.03.022","volume":"148","author":"A Drosdowsky","year":"2022","unstructured":"Drosdowsky, A. & Gough, K. The Charlson Comorbidity Index: problems with use in epidemiological research. J. Clin. Epidemiol. 148, 174\u2013177. https:\/\/doi.org\/10.1016\/j.jclinepi.2022.03.022 (2022).","journal-title":"J. Clin. Epidemiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89325-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89325-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89325-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T13:02:38Z","timestamp":1739624558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89325-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89325"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89325-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5637"}}